Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
61 hedge funds and large institutions have $222M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 9 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
106% more capital invested
Capital invested by funds: $108M → $222M (+$114M)
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
9% more funds holding
Funds holding: 56 → 61 (+5)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$20.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$15.2M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$7.15M |
| 4 |
Axa
Paris,
France
|
+$5.79M |
| 5 |
PA
Perceptive Advisors
New York
|
+$4.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$2.57M |
| 2 |
Millennium Management
New York
|
-$1.02M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$907K |
| 4 |
SAM
Senzar Asset Management
New York
|
-$627K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$589K |
FOMX Hedge Fund Activity: Q3 2016 in Review
61 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q3 2016, worth a combined $222M — up 106% from $108M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new FOMX positions and 9 closed out — a net gain of 5 holders — while 19 added to existing stakes and 18 trimmed.
The largest buyer was Great Point Partners, adding an estimated $20.9M. The largest seller was Sio Capital Management, exiting entirely with an estimated $2.57M sold.
- 61 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q3 2016, up from 56 in Q2 2016.
- Funds reported $222M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q3 2016, up 106% quarter-over-quarter.
- 14 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q3 2016 and 9 closed out, a net change of +5 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q3 2016 was Great Point Partners, an estimated $20.9M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q3 2016 was Sio Capital Management, an estimated $2.57M sold.
Based on aggregated 13F filings for Q3 2016.